Bridging the gap: addressing real-life challenges to the implementation of DTG/3TC in treatment-naive people living with HIV

Dolutegravir/lamivudine (DTG/3TC), used as a two-drug regimen (2DR), has demonstrated non-inferiority to traditional three-drug regimens (3DRs) in treatment-naive people with HIV (PWH), with sustained virological efficacy, favorable tolerability, and a good safety profile. However, its implementatio...

Cijeli opis

Bibliografski detalji

Glavni autori:	Andrea Giacomelli, Gianmaria Baldin, Valeria Bono, Arturo Ciccullo, Maria Mazzitelli, Mariacristina Poliseno, Marco Ridolfi, Federica Sozio, Elisabetta Teti, Giulia Marchetti
Format:	Artigo
Jezik:	Inglês
Izdano:	Frontiers Media S.A. 2026-01-01
Serija:	Frontiers in Virology
Teme:	antiretroviral therapy simplification dolutegravir/lamivudine treatment-naive people with HIV two-drug regimen (2DR) viro-immunological outcomes
Online pristup:	https://www.frontiersin.org/articles/10.3389/fviro.2025.1749039/full
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!